Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Disease-modifying treatment

- PMLiVE

Another $2m donated to further neurodegenerative commitment

Research funders build on global initiative for brain deteriorating diseases

- PMLiVE

Dementia research alliance to fast-track new Alzheimer’s drugs

Will see Alzheimer's Research UK partner with Cambridge, Oxford and UCL universities

- PMLiVE

AB Science on track for phase III data in Alzheimer’s this year

Trial of masitinib has passed a futility test

- PMLiVE

AZ and Lilly start BACE inhibitor trial in Alzheimer’s

Early trials show promise for the BACE inhibitor AZD3293

- PMLiVE

AZ and Lilly set up BACE camp for Alzheimer’s

Lilly will pay AZ up to $500m in development and regulatory costs

Roche - Basel

Mixed findings for Roche in Alzheimer’s study

Crenezumab misses targets but shows some signs of activity

- PMLiVE

GE Healthcare re-launches online neurological campaign

MIND Online aims to improve understanding of conditions such as Alzheimer's disease

- PMLiVE

CHMP backs Piramal’s Alzheimer’s imaging agent

Neuraceq recommended for approval in Europe

Eli Lilly HQ

Lilly exploring diabetes portfolio for Alzheimer’s potential

Undertakes pre-clinical investigations as it monitors the area

- PMLiVE

Takeda continues Actos resurrection as Alzheimer’s drug

Late-stage trial will see if pioglitazone can delay disease progression

- PMLiVE

Non-amyloid therapies emerging for Alzheimer’s at AAIC

AAIC meeting hears new clinical data from Lundbeck, Baxter, Chiesi and Takeda

- PMLiVE

Medicare puts brake on Lilly’s Alzheimer’s test

Will only reimburse new Alzheimer's diagnostic Amyvid for patients in trials

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links